SGLT2 inhibitor - Wikipedia
Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes | Clinical Diabetes
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors - Kidney International
Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure | Heart
Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 Inhibitor Canagliflozin with SGLT1 and SGLT2: Inhibition Kinetics, Sidedness of Action, and Transporter-Associated Incorporation Accounting for its Pharmacodynamic and Pharmacokinetic Features ...
Update on Mx of T 2 DM Emerging
Long-Term Clinical Benefits of Canagliflozin 100 mg Versus Sulfonylurea in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin in India - Value in Health Regional Issues
Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors - Yakovleva -
A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium‐glucose co‐transporter‐2 inhibitors - Brown - 2019 - Diabetes, Obesity and Metabolism - Wiley Online Library
Mode of action of SGLT2 inhibitors in the kidney. Copied with... | Download Scientific Diagram
Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus - ScienceDirect
SGLT2 inhibitors
Canagliflozin review – safety and efficacy profile in patients w | DMSO
![canagliflozin [TUSOM | Pharmwiki]](https://tmedweb.tulane.edu/pharmwiki/lib/exe/fetch.php/sglt2.png "canagliflozin [TUSOM | Pharmwiki]")
canagliflozin [TUSOM | Pharmwiki]
Swiss Medical Weekly - Use of SGLT2 inhibitors in cardiovascular diseases: why, when and how?
SGLT2 Inhibitors: A New Class of Diabetes Medications
SGLT 2 inhibitors
Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease | SpringerLink
Swiss Medical Weekly - Use of SGLT2 inhibitors in cardiovascular diseases: why, when and how?
Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure | SpringerLink
Clinical Implications of Canagliflozin Treatment in Patients With Type 2 Diabetes | Clinical Diabetes
Canagliflozin - an overview | ScienceDirect Topics
A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus Prasanna Kumar K M, Ghosh S, Canovatchel W, Garodia N, Rajashekar
SGLT2 Inhibition in the Diabetic Kidney—From Mechanisms to Clinical Outcome | American Society of Nephrology
SGLT2 Inhibitors: A Review of Canagliflozin
SGLT2 inhibitors for treatment of Type 2 diabetes mellitus: Focus on Canagliflozin Singh SK, Gupta A K - Muller J Med Sci Res
Ueda2015 canagliflozin dr.inass shaltout
